A new inspection of the Oral Solid Dosage facility found that it complied with current Good Manufacturing Practices.
The US Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd's (Nasdaq: TEVA; TASE: TEVA) Oral Solid Dosage (OSD) manufacturing facility in Jerusalem.Teva has received a closeout letter from the US Food and Drug Administration (FDA) stating that the company has addressed the issues raised by the FDA in a warning letter in January.
In the January inspection of the facility, the FDA raised questions about its current Good Manufacturing Practices (cGMP). The FDA found no adverse finding in a new inspection of the facility in June.
Teva's share price fell 1.5% on Nasdaq yesterday to $37.92, giving a market cap of $33.8 billion, and rose 0.6% at the opening on the TASE today to NIS 140.
Published by Globes [online], Israel business news - www.globes-online.com - on September 13, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011